RecruitingNot ApplicableNCT05365347

Piloting of an Intervention to Reduce Problematic Alcohol Use in Early Phase Psychosis Patients

Piloting of an Intervention to Reduce Problematic Alcohol Use in Early Phase Psychosis


Sponsor

Nova Scotia Health Authority

Enrollment

24 participants

Start Date

Dec 1, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

A focus of research for youth and Emerging Adults with early phase psychosis (EPP) has been cannabis use. However, this focus has led to overlooking the possible negative influence of another legal recreational drug, alcohol. Previous studies our research group has done have demonstrated that over use of alcohol reduces the effectiveness of early intervention in psychosis treatment services. These treatment services are wrap around services that address medical, and social needs of young people with psychosis. Individuals with alcohol use disorder and EPP have fewer positive symptoms such as hallucinations which are the aspects of psychotic disorders that respond most readily to medication but have greater levels of depressive symptoms. Biologically, we can see the negative impact of alcohol on brain structure in our MRI studies. Our aim presented in this grant is to pilot a psychosocial intervention using cognitive enhancement therapy to reduce alcohol consumption in individuals with early phase psychosis. This intervention has shown promise in reducing alcohol use in individuals with long standing schizophrenia and compare it to treatment as usual which involves brief (1 session) psychoeducation. The investigators hope to reduce substance use in young people in the early stages of a psychotic disorder and improve their odds of a full recovery. In addition to measuring symptoms and hospitalizations, this trial will measure what are called social determinants of health such as return to school or work and resumption of relationships. These variables have not been measured previously in alcohol use interventions in this population but in our experience are the best indicators of long term recovery from psychosis. The symptoms will generally improve with antipsychotic drug treatment but reach a threshold after 6 months in most individuals who engage with our 5 year program. Further functional and social recovery seem to be the best determinants of a full return to health in this population.


Eligibility

Min Age: 16 YearsMax Age: 35 Years

Plain Language Summary

Simplified for easier understanding

This study is piloting a program to reduce harmful alcohol use in young people who are in early treatment for psychosis (conditions like schizophrenia or schizoaffective disorder), combining motivational therapy with peer support. **You may be eligible if...** - You are between 16 and 35 years old - You are receiving Early Intervention Services for psychosis in Nova Scotia, Canada - You have had a psychotic illness for less than 5 years - You have been diagnosed with schizophrenia, schizoaffective disorder, or a related psychotic spectrum disorder - You score 8 or higher on a standard alcohol use questionnaire (WHO-AUDIT), indicating problematic drinking **You may NOT be eligible if...** - You have another active substance use disorder (beyond alcohol and nicotine) - You are outside the age range or duration of illness criteria Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALCognitive Enhancement Therapy (CET)

Cognitive enhancement therapy is an evidence based intervention for schizophrenia focused on improving the cognitive domains of memory, attention span and learning ability. It has shown efficacy in reducing substance use as an indirect outcome but this will be the focus of this intervention.


Locations(1)

Nova Scotia Health Authority

Halifax, Nova Scotia, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05365347


Related Trials